NNZ-2591 + Placebo

Phase 3Recruiting

0 views this week 1 watching⚡ Active🔬Featured in Small-Cap Pipeline Watch

Interest: 41/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Phelan-McDermid Syndrome

Conditions

Phelan-McDermid Syndrome

Trial Timeline

Nov 12, 2025 → Nov 15, 2027

NCT ID

NCT07281079

About NNZ-2591 + Placebo

NNZ-2591 + Placebo is a phase 3 stage product being developed by Neuren Pharmaceuticals for Phelan-McDermid Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07281079. Target conditions include Phelan-McDermid Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07281079	Phase 3	Recruiting	Nov 12, 2025	Nov 15, 2027	Phelan-McDermid Syndrome
NCT04379869	Phase 1	Completed	May 29, 2020	Feb 11, 2021	Healthy Volunteers

Competing Products

1 competing product in Phelan-McDermid Syndrome

See all competitors

Product	Company	Stage	Hype Score
NNZ-2591	Neuren Pharmaceuticals	Phase 2	29